COX-2 inhibitors and cardiovascular risk.
Flattery
Maureen P
MP
Medical College of Virginia, Virginia Commonwealth University Health System, Heart Failure/Transplant, Richmond, VA 23298, USA. mflatter@hsc.vcu.edu
Hylton Gravatt
Leigh Anne
LA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D008565:Membrane Proteins; D018579:Patient Selection; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects*; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D012449:Safety; D013997:Time Factors; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases